有投资者在互动平台向永安药业（002365）提问，公司新开发的易加能牛磺酸功能饮料产品除了线上销 售外，今后是否有计划进行线下销售？永安药业回复，子公司永安康健易加能产品目前已开始在部分地 区连锁药房铺货并进行终端推广。 ...

Mergers and Acquisitions - Bozhong Precision plans to acquire 70% stake in Shanghai Wodian for 420 million yuan, aiming to enter the automotive intelligent equipment market and establish a diversified business model of "3C + new energy + automotive" [1] Shareholding Changes - Hengrui Medicine's senior vice president plans to reduce holdings by up to 47,670 shares, representing 0.007% of the total share capital due to personal financial needs [2] - Guomao Co., Ltd.'s actual controller plans to reduce holdings by up to 19,772,600 shares, accounting for 3% of the total share capital, with a minimum selling price not lower than the IPO price [3] - Baoli International's shareholder plans to reduce holdings by up to 27,468,000 shares, representing 3% of the total share capital after excluding repurchased shares, due to personal financial needs [4] Risk Matters - Yong'an Pharmaceutical warns of high speculation risk as its stock price has surged significantly, deviating from the market trend, although there are no major changes in fundamentals [5] - ST Kevin alerts investors about rational investment and risk awareness due to a cumulative price deviation of 12.32% over three trading days, confirming no violations of fair information disclosure [6] - Annie Co. states that there are no undisclosed significant matters, despite a cumulative price deviation exceeding 20% over two trading days, and confirms stable operational conditions [7]

智通财经6月15日电，永安药业(002365.SZ)公告称，近期公司股价短期涨幅较大，已严重偏离大盘走 势，存在较高的炒作风险。但公司基本面没有重大变化，也不存在应披露未披露的重大信息。2025年一 季度，公司处于亏损状态。根据中证指数有限公司的数据显示，截至本公告披露时，公司最新的静态市 净率、滚动市盈率、市净率均高于公司所属中上协行业分类"医药制造业"水平。公司已连续多日发布股 票交易异常波动公告，特别提醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 永安药业：公司股价短期涨幅较大已严重偏离大盘走势 存在较高的炒作风险 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-40 潜江永安药业股份有限公司 关于股票交易异常波动暨风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易价格于 2025 年 6 月 12 日、2025 年 6 月 13 日连续 两个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳证券交易所的有关 规定，属于股票交易异常波动的情况。 2、近期公司股价短期涨幅较大，已严重偏离大盘走势，存在较高的炒作风 险。但公司基本面没有重大变化，也不存在应披露未披露的重大信息。2025 年 一季度，公司处于亏损状态。根据中证指数有限公司的数据显示，截至本公告披 露时，公司最新的静态市净率、滚动市盈率、市净率均高于公司所属中上协行业 分类"医药制造业"水平。公司已连续多日发布股票交易异常波动公告，特别提 醒广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的情况介绍 公司股票交易价格于 2025 年 6 月 ...

Core Viewpoint - Yong'an Pharmaceutical focuses on building a health industry chain centered around taurine, with plans to develop a series of products based on its physiological functions [1] Product Strategy - The company employs a big product strategy under the Yi Jian Neng brand, aiming to create various functional products beyond the existing offerings [1] - Future products will target specific benefits such as anti-fatigue, liver protection, alleviation of eye fatigue, memory enhancement, and immune system support [1]

Group 1: Company Strategy and Market Position - The company has a strong foundation in taurine production, with over 20 years of experience in R&D, production, and sales, making it difficult for competitors to disrupt its position quickly [2] - Taurine has a wide range of applications, and the company is well-prepared to capitalize on the macro policy of expanding domestic demand [2] - The company aims to maintain its traditional taurine supplier status while also focusing on developing its own brand products in the health and consumer market [2] Group 2: Product Development and Marketing - The company has registered numerous trademarks and developed various health products, focusing on taurine as the core of its health industry chain [3] - The marketing strategy for the "Yijianeng" brand includes leveraging online platforms and offline channels, with a focus on differentiated competition [3][5] - The company is actively promoting "Yijianeng" through various channels, including pharmacies, convenience stores, and gas stations [5] Group 3: Financial Performance and Projections - In 2024, the company produced 51,200 tons of taurine, with sales of 49,700 tons, indicating a domestic and international sales ratio of approximately 20% to 80% [9] - The company plans to support its C-end business development with the new taurine production capacity, which is expected to enhance revenue and profit [9] Group 4: Future Plans and Innovations - The company is exploring the introduction of customized functional products targeting different consumer groups, such as fitness enthusiasts and the elderly [12] - Future product development will focus on creating a series of products based on taurine's physiological functions, including fatigue relief and immune enhancement [12] - The company is committed to continuous R&D investment and has developed several patents related to taurine production, which will strengthen its competitive edge [18] Group 5: Marketing and Brand Awareness - The company recognizes the importance of market presence and investor engagement, aiming to enhance brand visibility and consumer loyalty [10] - Plans to collaborate with influencers and celebrities for marketing campaigns are being considered to boost brand recognition [26] - The company is open to suggestions for improving marketing strategies and product positioning to better connect with consumers [24]

Market Overview - As of June 12, the Shanghai Composite Index closed at 3402.66 points, with a slight increase of 0.34 points, representing a change of 0.01% [1] - The Shenzhen Component Index closed at 10234.33 points, down by 11.69 points, a decrease of 0.11% [1] - The ChiNext Index closed at 2067.15 points, up by 5.29 points, reflecting an increase of 0.26% [1] Trading Activity - A total of 128 A-shares had a turnover rate exceeding 20% on the same day, indicating significant trading activity [1] - Notably, C Haiyang and Zhongke Magnetic had turnover rates exceeding 50%, suggesting a high level of liquidity and interest in these stocks [1] Top Performing Stocks - C Haiyang (603382) had a closing price of 55.97 yuan with a turnover rate of 85.43% and a remarkable increase of 386.70% [1] - Zhongke Magnetic (301141) closed at 68.13 yuan, with a turnover rate of 67.96% and a gain of 3.20% [1] - Yingsite (301622) closed at 97.32 yuan, achieving a turnover rate of 60.53% and a rise of 20.00% [1] - Jiangnan New Materials (603124) closed at 48.20 yuan, with a turnover rate of 57.58% and an increase of 4.83% [1] - Xiongdi Technology (300546) closed at 34.41 yuan, with a turnover rate of 56.64% and a gain of 7.20% [1] Additional Notable Stocks - Kangliyuan (301287) closed at 50.52 yuan, with a turnover rate of 48.58% and a slight decrease of 0.26% [1] - Qingmu Technology (301110) closed at 72.42 yuan, achieving a turnover rate of 46.33% and a rise of 20.00% [1] - Baixinglong (833075) closed at 46.99 yuan, with a turnover rate of 44.54% and an increase of 29.99% [1] - Hengbao Co., Ltd. (002104) closed at 11.82 yuan, with a turnover rate of 44.51% and a gain of 2.34% [1] - Guokang Biochemical (300804) closed at 61.10 yuan, with a turnover rate of 42.76% and a slight increase of 1.08% [1]

Group 1 - The A-share chemical pharmaceutical sector is experiencing a volatile correction, with companies such as Haichen Pharmaceutical and Yong'an Pharmaceutical both declining over 9% [1] - Other companies including Yipinhong, Hasanlian, Tonghua Jinma, Hanyu Pharmaceutical, and Hehua Co. have also seen declines of around 5% [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-39 潜江永安药业股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业，证 券代码：002365）股票交易价格于 2025 年 6 月 6 日、2025 年 6 月 9 日、2025 年 6 月 10 日连续三个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳 证券交易所的有关规定，属于股票交易异常波动的情况。 二、公司关注、核实情况说明 （四）经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而 未披露的重大事项，或处于筹划阶段的重大事项；股票异常波动期间控股股东、 实际控制人不存在买卖公司股票的行为。 （五）经核查，公司未发现其他应披露而未披露事项。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协 议等；董事会也未获悉本公司有根 ...

永安药业（002365）发布异动公告，公司近期经营情况正常，内外部经营环境未发生重大变化；公司、 控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项。 ...